Landmark trial could expand revolutionary treatments to all hepatitis C patients

February 3, 2016

New targeted treatments have revolutionized care for hepatitis C, offering cure rates of close to 100 percent for people infected with the most common strain of the virus. Dr. Curtis Cooper and his team have played a major role in the research that made this possible, and they have now made another important contribution, recently published in the New England Journal of Medicine. Working with an international team, they found that a new pill that combines two targeted drugs can cure 95 to 100 percent of people with six different strains of the virus, including the notoriously hard-to-treat HCV-3. This research promises not only to improve care, but also to streamline care, as all patients could potentially be treated with the same drug. These results encompass three clinical trials published simultaneously in the journal and summarized in this editorial.

About The Ottawa Hospital

The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.

For further information, please contact

Jennifer Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
Office: 613-798-5555 x 73325
Cell: 613-614-5253